Related Experiment Video
Updated: Jun 29, 2025

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood
Published on: February 5, 2020
Reporting and analysis of immunotherapy trials adverse events: what is going wrong, how to do better?
I Pourmir1, R Nebbache2, S Champiat3
1Thoracic Oncology Department, Georges Pompidou European Hospital, Paris CARPEM Cancer Institute, AP-HP Centre, Université Paris Cité, Paris; INSERM Immunotherapy and Anti-Angiogenic Therapy in Oncology, PARCC, Paris.
No abstract available in PubMed .
More Related Videos
05:21Author Spotlight: Optimizing Antibody-Based Cancer Treatments via Antibody-Dependent, Cell-Mediated Cytotoxicity Assay
Published on: September 13, 2024
06:08Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model
Published on: February 10, 2023
Related Concept Videos
Tumor Immunotherapy
Clinical Trials
There are four phases in a clinical trial. A phase one...